US Department of Justice Opens Investigation into Cassava Alzheimer’s Drug Data Manipulation Controversy
Late last year, reports surfaced that Cassava Sciences had falsified trial data regarding its experimental drug for Alzheimer’s disease. Now, the US Department of Justice (DOJ) has launched a probe into the allegations, sending the company’s share prices down by 30%. The claims originated from two doctors, represented by the law firm Labaton Sucharow, who found irregularities in data coming from Hoau-yan Wang, an Associate Medical Professor at City University of New York, and Lindsay Burns, Cassava’s VP of neurosciences.
Congressional Democrats Seek DOJ and FTC Investigation into Blood Thinner Price Hikes
Johnson & Johnson and Bristol Meyers Squib are facing increasing scrutiny from members of the US Congress after allegations of [...]
Department of Justice Files Lawsuit to Block UnitedHealth-Change Healthcare Merger
The Department of Justice has just filed suit to block UnitedHealth’s acquisition of the health IT services company Change Health. [...]
